Paradigm BioCapital Advisors LP 13D and 13G filings for Lexeo Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:25 pm Purchase | 2026-03-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 6,184,134 8.300% | 1,420,936 (+29.83%) | Filing |
| 2026-02-17 4:02 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 4,763,198 6.500% | 1,091,199 (+29.72%) | Filing |
| 2025-11-20 4:30 pm Purchase | 2025-11-13 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 3,671,999 5.000% | 3,671,999 (New Position) | Filing |